Sera Prognostics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $30,000 for Q2 2026, up from $17,000 in Q2 2025, reflecting gradual growth aligned with commercialization efforts.

Operating Expenses: $10 million, slightly increased from $9.3 million year-over-year, indicating disciplined cost management.

Net Loss: $9.1 million, compared to a net loss of $8.0 million in Q2 2025.

Cash Position: $80.3 million in cash and equivalents, expected to fund operations through significant adoption milestones until 2029.

2Strategic Updates and Business Highlights

Partnerships and Payer Engagement: Launched the fourth partnership program and expanded payer discussions, exceeding the goal of engaging with 20 payers across 20 states.

Legislative Milestone: Illinois Medicaid coverage legislation passed, allowing access to PreTRM Test-guided care for thousands of Medicaid pregnancies, seen as a model for other states.

Clinical Evidence: Published PRIME data showing significant reductions in NICU admissions and neonatal morbidity, strengthening the case for PreTRM Test adoption.

European Strategy: Progressing with regulatory submissions for CE marking, with additional performance testing planned to enhance the submission package.

3Forward Guidance and Outlook

Market Access: Focus will shift to implementation and adoption in the second half of 2026, with expectations of gradual increases in testing volumes.

Illinois Impact: Anticipated slow ramp-up in utilization post-reimbursement, with projections of 1-2% penetration in 2027 and up to 5% by year three.

Continued Evidence Generation: Plans to publish further studies to support guideline inclusion and bolster payer discussions.

4Bad News, Challenges, or Points of Concern

Modest Revenue Growth: Current revenue remains low, reflecting the early stage of commercialization and the time required for payer contracting and provider activation.

Long Implementation Timeline: The process from securing access to achieving meaningful utilization can take 6-9 months, potentially delaying revenue growth.

Competitive Pressures: Need to maintain momentum in payer engagement and clinical validation amidst evolving market dynamics.

5Notable Q&A Insights

Provider Activation Process: The transition from provider notice to active reimbursement involves multiple steps, including provider registration and contracting with payers, which can take significant time.

Benchmarking Utilization: Insights shared on expected penetration rates based on industry benchmarks, indicating cautious optimism for gradual adoption in new markets.

Guideline Updates: Emphasis on the importance of continued publication of clinical data to influence guideline updates from key organizations like ACOG and SMFM.

CE Mark Submission: Clarified that additional data for the CE marking submission was internally driven to mitigate risks, not a result of advisory feedback. In summary, Sera Prognostics is making significant strides in expanding its market presence and clinical validation for its PreTRM Test, albeit with modest financial results and anticipated challenges in ramping up utilization. The company remains focused on strategic partnerships, payer engagement, and evidence generation to support long-term growth.